Sequana Medical Presents alfapump QOL benefit in liver ascites at EASL
Sequana will present previously reported outcomes from a matched cohort analysis of the POSEIDON study and NACSELD3 registry showing a quality of life benefit with comparable safety for the alfapump vs. standard of care (paracentesis) in liver ascites, at EASL being held 5-8 June. We believe the data continues to support the alfapump's positioning and look forward to PMA approval expected in 1Q25, and subsequent US commercial launch in 2H25. We reiterate our BUY rating and € 6 TP.Sequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.